Lupin jumps on completing acquisition of brands from Anglo-French Drugs & Industries
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 781.10, up by 8.15 points or 1.05% from its previous closing of Rs. 772.95 on the BSE.
The scrip opened at Rs. 772.10 and has touched a high and low of Rs. 786.85 and Rs. 768.90 respectively. So far 26746 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 678.65 on 07-Mar-2022.
Last one week high and low of the scrip stood at Rs. 798.90 and Rs. 736.35 respectively. The current market cap of the company is Rs. 35499.04 crore.
The promoters holding in the company stood at 46.81%, while Institutions and Non-Institutions held 40.39% and 12.79% respectively.
Lupin completes acquisition of a portfolio of brands from Anglo-French Drugs & Industries (AFDIL) and its Associates. The acquisition will strengthen Lupin’s India Formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical company in India.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
